| Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline M Tuccori, S Ferraro, I Convertino, E Cappello, G Valdiserra, C Blandizzi, ... MAbs 12 (1), 1854149, 2020 | 153 | 2020 |
| The impact of the COVID-19 “Infodemic” on drug-utilization behaviors: implications for pharmacovigilance M Tuccori, I Convertino, S Ferraro, E Cappello, G Valdiserra, D Focosi, ... Drug safety 43, 699-709, 2020 | 100 | 2020 |
| Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients I Convertino, M Tuccori, S Ferraro, G Valdiserra, E Cappello, D Focosi, ... Critical Care 24, 1-6, 2020 | 51 | 2020 |
| Allopurinol adherence among patients with gout: an Italian general practice database study S Mantarro, A Capogrosso‐Sansone, M Tuccori, C Blandizzi, ... International journal of clinical practice 69 (7), 757-765, 2015 | 48 | 2015 |
| The usefulness of listening social media for pharmacovigilance purposes: a systematic review I Convertino, S Ferraro, C Blandizzi, M Tuccori Expert opinion on drug safety 17 (11), 1081-1093, 2018 | 46 | 2018 |
| Italian emergency department visits and hospitalizations for outpatients’ adverse drug events: 12-year active pharmacovigilance surveillance (The MEREAFaPS Study) N Lombardi, G Crescioli, A Bettiol, M Tuccori, A Capuano, R Bonaiuti, ... Frontiers in pharmacology 11, 412, 2020 | 40 | 2020 |
| Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects I Convertino, AC Sansone, A Marino, MT Galiulo, S Mantarro, L Antonioli, ... Drug safety 39, 903-924, 2016 | 33 | 2016 |
| Large-scale postmarketing surveillance of biological drugs for immune-mediated inflammatory diseases through an Italian distributed multi-database healthcare network: the … G Trifirò, V Isgrò, Y Ingrasciotta, V Ientile, L L’Abbate, SS Foti, V Belleudi, ... BioDrugs 35, 749-764, 2021 | 32 | 2021 |
| Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis A Capogrosso Sansone, S Mantarro, M Tuccori, E Ruggiero, ... Drug Safety 38, 869-888, 2015 | 29 | 2015 |
| Expected and actual adverse drug-drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study A Marino, A Capogrosso-Sansone, M Tuccori, G Bini, V Calsolaro, ... Expert opinion on drug safety 15 (sup2), 45-50, 2016 | 28 | 2016 |
| Drug-related hypersensitivity reactions leading to emergency department: original data and systematic review S Pagani, N Lombardi, G Crescioli, VG Vighi, G Spada, P Andreetta, ... Journal of clinical medicine 11 (10), 2811, 2022 | 24 | 2022 |
| Muscular adverse drug reactions associated with proton pump inhibitors: a disproportionality analysis using the Italian National Network of Pharmacovigilance Database A Capogrosso Sansone, I Convertino, MT Galiulo, S Salvadori, S Pieroni, ... Drug safety 40, 895-909, 2017 | 23 | 2017 |
| Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments N Lombardi, A Bettiol, G Crescioli, C Ravaldi, R Bonaiuti, M Venegoni, ... Internal and emergency medicine 15, 1291-1302, 2020 | 21 | 2020 |
| An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and … M Tuccori, I Convertino, S Ferraro, G Valdiserra, E Cappello, E Fini, ... Expert Opinion on Drug Discovery 16 (12), 1403-1414, 2021 | 19 | 2021 |
| Is there a risk of lymphoma associated with anti-tumor necrosis factor drugs in patients with inflammatory bowel disease? A systematic review of observational studies S Ferraro, L Leonardi, I Convertino, C Blandizzi, M Tuccori Frontiers in Pharmacology 10, 247, 2019 | 18 | 2019 |
| Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non … I Convertino, E Lucenteforte, R Gini, V Lorenzoni, M Cazzato, G Turchetti, ... Clinical and Experimental Rheumatology 39 (4), 753-762, 2021 | 14 | 2021 |
| Clinical differences among the elderly admitted to the emergency department for accidental or unexplained falls and syncope G Pasqualetti, V Calsolaro, G Bini, U Dell’Agnello, M Tuccori, A Marino, ... Clinical interventions in aging, 687-695, 2017 | 14 | 2017 |
| Risk of hospitalization associated with cardiovascular medications in the elderly Italian population: A nationwide multicenter study in emergency departments G Crescioli, A Bettiol, R Bonaiuti, M Tuccori, M Rossi, A Capuano, ... Frontiers in pharmacology 11, 611102, 2021 | 13 | 2021 |
| Potential direct costs of adverse drug events and possible cost savings achievable by their prevention in Tuscany, Italy: a model-based analysis I Convertino, S Salvadori, A Pecori, MT Galiulo, S Ferraro, M Parrilli, ... Drug Safety 42, 427-444, 2019 | 13 | 2019 |
| Tixagevimab+ cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence I Convertino, S Ferraro, E Cappello, G Valdiserra, M Bonaso, M Tuccori Expert Opinion on Drug Discovery 18 (3), 231-245, 2023 | 12 | 2023 |
